Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medicaid Pharmacy topic
No spam. Unsubscribe anytime.
Bill would let Nebraska add behavioral‑health drug classes to Medicaid preferred list; clinical groups warn of risks
Summary
LB1043 would permit the state Pharmaceutical and Therapeutics Committee to consider antidepressants, antipsychotics and anticonvulsants for Nebraska’s Medicaid Preferred Drug List. DHHS favors the change for administrative consistency and rebate revenue; psychiatrists and behavioral‑health advocates warned that fail‑first rules could destabilize patients unless strong clinical exemptions are preserved.
Sen. Glenn Meyer (Dist. 17) told the Health and Human Services Committee that LB1043 would remove a statutory prohibition and allow Nebraska’s Pharmaceutical and Therapeutics Committee to consider including antipsychotic, antidepressant and anticonvulsant drugs on the state’s Medicaid Preferred Drug List (PDL).
Lee Stutzman, pharmacy director at Nebraska Medicaid and Long‑Term Care, testified in support and said adding those classes to the unified state PDL (fee‑for‑service and managed care) would reduce administrative burden for providers and beneficiaries and allow the state to negotiate supplemental rebates, estimating more than $1.2 million in annual net savings.
Opponents, including psychiatrist Dr. Kimberly Klawson representing the Nebraska Association of Behavioral Health Organizations, warned that preferred‑drug placement can introduce prior‑authorization or ‘fail‑first’ requirements. She said behavioral‑health medications are often individualized and that medication changes can destabilize patients, increasing hospitalizations and crisis‑system use. Peer testimony from people with lived experience echoed concerns that interruptions and coverage limits can hinder recovery.
DHHS and the bill sponsor said emergency and continuity safeguards exist: non‑preferred medications remain available through prior authorization and contracts require timely responses so that patients do not experience gaps. Committee members asked about the legislative history and the federal changes that made PDL inclusion feasible; Stutzman said manufacturer practices and federal program changes prompted reconsideration of exclusions.
The committee did not vote during the hearing. Members signaled interest in amendments or guardrails to protect clinically complex behavioral‑health patients while pursuing potential pharmacy cost savings.
